Webcasts

Urine Biomarkers for the Detection of Urothelial Carcinoma. Urofair Singapore. Sia Daneshmand, MD, University of Southern California presents to SUA at Urofair on urinary biomarkers in bladder ancer.

Cxbladder for Hematuria Assessment and Follow-up of Low-grade Bladder Cancer. Urofair Singapore. Madhusudan Koya, Clinical Director, Waitemata DHB discusses new data on Cxbladder adoption in Canterbury and Waitemata.

Urinary Markers in Bladder Cancer. Grand Rounds in Urology. Peter Black, MD, discusses the benefits and limitations of the currently FDA approved and commercially available urinary biomarkers for bladder cancer.

Urinary Molecular Marker Tests in Bladder Cancer: An Overview of Cxbladder.  Grand Rounds in Urology. Sia Daneshmand, MD, University of Southern California gives an overview of hematuria and some of the new urinary molecular marker tests in bladder cancer.

The Development and Clinical Validation of a High Sensitivity Urine biomarker test for the Determination of Recurrence in Urothelial Carcinoma Patients. Plenary at the American Urological Association (AUA) Annual Meeting, San Diego, May 2016.

Healthcare Professional Information

Cxbladder Brochure

Cxbladder Triage Brochure

Cxbladder Triage Case Study

Clinical Study Summary

'How it Works' Summary

Editorials

Urine's Role in Bladder Cancer Management, by Neal D. Shore, MD, FACS

 

Urinary Molecular Marker Tests in Bladder Cancer: An Overview of Cxbladder

Sia Daneshmand, MD, University of Southern California, Los Angeles, CA, gives an overview of hematuria and some of the new urinary molecular marker tests in bladder cancer.

Urinary Molecular Marker Tests in Bladder Cancer: An Overview of Cxbladder
Urinary Molecular Marker Tests in Bladder Cancer: An Overview of Cxbladder